J. Pérez

发表

Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates.

F. Saad, R. Aft, N. Raje, 2012, Critical reviews in oncology/hematology.

Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma

H. Henk, S. Kaura, A. Teitelbaum, 2012, American journal of hematology.

Systemic treatment modalities in the management of AIDS‐related Kaposi's sarcoma

J. Pérez, D. Hernåndez, Dimas E. Hernàndez, 1997 .

Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US

E. Jonasch, N. Vogelzang, W. Reichmann, 2016, Journal of medical economics.

Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for second-line treatment of metastatic renal cell carcinoma (mRCC) in the United States: A retrospective chart review.

E. Jonasch, N. Vogelzang, W. Reichmann, 2015 .

Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA

N. Vogelzang, S. Pal, J. Signorovitch, 2017, International journal of urology : official journal of the Japanese Urological Association.

The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma

E. Swallow, A. Messali, E. Duchesneau, 2018, Journal of managed care & specialty pharmacy.

Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.

N. Vogelzang, W. Reichmann, S. Pal, 2016, Clinical genitourinary cancer.

Real‐World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER–Medicare Database Analysis

N. Agarwal, N. Vogelzang, S. Pal, 2017, Clinical genitourinary cancer.

Results of a Qualitative Study to Develop a Patient Reported Outcome Measure for Patients with 4 Subtypes of Soft Tissue Sarcoma

A. Rentz, A. Skalicky, S. Ghate, 2017, Sarcoma.

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis

N. Agarwal, N. Vogelzang, S. Pal, 2017, Advances in Therapy.

An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

G. Barosi, C. Harrison, H. Gisslinger, 2012 .

A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma (ACC).

C. Moskaluk, G. Petroni, P. Fracasso, 2015 .

Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review

E. Jonasch, N. Vogelzang, W. Reichmann, 2016, Current medical research and opinion.

Kaposi Sarcoma Associated with Human Immunodeficiency Virus Infection

J. Pérez, D. Hernåndez, Jaime Wilder, 1991, International journal of dermatology.

Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data

N. Agarwal, N. Vogelzang, S. Pal, 2018, Journal of Managed Care & Specialty Pharmacy.

918 Prostate-specific antigen kinetics in patients with bone metastases from castration-resistant prostate cancer receiving zoledronic acid therapy

J. Eastham, F. Saad, S. Segal, 2012 .